drugset / Trial / NCT06589830
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II trial designed to determine the optimal dose and evaluate the effectiveness of TL938 and trastuzumab in treating patients with HER2+ colorectal cancer that has metastasized or recurred and is inoperable.
Timeline
- Start
- 2025-05-13
- Primary completion
- 2026-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TL938 | Unknown | — | Oral |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |